Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

The Myriad Challenges of Informed Consent

July 1, 2007
Publication
Article
OncologyONCOLOGY Vol 21 No 8
Volume 21
Issue 8

Virginia Sun outlines the elements that must be included in an informed consent document for clinical research. The purpose in stipulating such categories is to ensure that an individual receives, both in writing and during the discussion, sufficient information to make a decision about participation in the research study.

In her cover article (p. 11), Virginia Sun outlines the elements that must be included in an informed consent document for clinical research. The purpose in stipulating such categories is to ensure that an individual receives, both in writing and during the discussion, sufficient information to make a decision about participation in the research study.

Even as oncology nurses who are not involved in research, we may find ourselves participating in this process by answering questions and guiding patients and families as they make their decisions. As we do this, we must be able to present information without bias so as to preserve patients' right to make decisions about their own care as autonomous individuals.

In addition, it's also important to acknowledge the emotional element of informed consent for patients and their families. As Ms. Sun observes, patients offered the opportunity to enroll in a trial may feel a sense of altruism, or anxiety, or unrealistic hope. It is important for nurses to understand and be sensitive to these emotional elements.

Because advancements in oncology occur as a result of clinical trials, participation in these studies is crucial to the future of all cancer prevention, diagnosis, and treatment interventions. Thus, public knowledge about the value of clinical trials is critical to making continued progress against cancer. Education begins, then, not only with descriptions of specific study regimens, but also with information about the purpose of clinical trials themselves, their role in medical research, and how results build incrementally throughout each phase of clinical investigation.

It would be wonderful if all oncology nurses were prepared to discuss clinical trials in a general way with patients and their families. To do this, there are some steps to take. First, we must inform ourselves. Nurses should be able to answer basic queries about trial phases, study designs, who is providing the funding for a particular clinical trial, and what protections are in place for research participants. A wonderful resource for this information is the National Cancer Institute's web site, www.cancer.gov/clinicaltrials.

The issue of informed consent is a crucial one for clinical trials, but it is equally relevant to decision-making about cancer care generally. Each component—the right to be informed and the right to consent to actions taken on one's own person—is a hallmark of ethical clinical care.

As oncology nurses we have both an opportunity and a responsibility to take a leading role in ensuring that informed consent is at the center of every patient's cancer treatment plan. Patient education is at the heart of oncology nursing practice. We should remind ourselves daily about the importance of information provided in a way that leads to understanding and ultimately to informed decision making by the patients in our care.

—Mary McCabe, RN, MA
Editor-in-Chief

Articles in this issue

The Myriad Challenges of Informed Consent
Hodkin's Lymphoma in the Elderly: Who is 'Older' and Is the Disease Really Worse in Older Patients?
Antiemetic Therapy: Much Progress, Much More to be Done
Chemotherapy-Induced Nausea and Vomiting: Great Achievements but Room for Improvement
he Oncology Nurse's Role in the Informed Consent Process
Radiation Dermatitis
A Clear Need for Randomized Trials
Monoclonal Antibodies to EGFR: What Does the Future Hold?
Hodgkin's in the Elderly: More Questions Than Answers
One Moment in Research
FDA Grants Priority Review of Ixabepilone Plus Two Other Agents
Premenopausal Estrogen Levels Linked to Higher Death Rate Among Women Receiving Chemotherapy for Advanced NSCLC
Phase III Ixabepilone Study Shows Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer
Management of Comorbid Diabetes and Cancer
S-1 Plus Cisplatin Demonstrates Significant Improvement in Overall Survival of Advanced Gastric Cancer Patients Over S-1 Alone

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

Ana Sandoval;Joyce A. O’Shaughnessy;Astra M. Liepa;Brenda Grimes;Katheryn Moreira;James Roose;Catherine Keane;Sara M. Tolaney, MD, MPH
May 29th 2025
Article

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD
May 27th 2025
Article

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

Anushree Iyengar;Sandhya Mehta;Hannah Barman;Nivedita Rangarajan;Sue-Ann Woo;Simone T. Sredni;Rosemarie Di Donato;Safak Simsek;Erinn P. Downs;Aziza Nassar;Darren M. Wilson;Katherine Krieser;Elise Bieri Patzke;Natalie Kyek;Jason Hipp;Tyler Wagner, PhD
May 25th 2025
Article

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

Katheryn Moreira;Kathryn Hudson;Wambui Gathirua-Mwangi;Zhanglin Lin Cui;Madeline Richey;Brenda Grimes;Jingru Wang;Astra Liepa;Erich Brechtelsbauer;Raisa Volodarsky;Hatem Soliman, MD
May 24th 2025
Article
Related Content

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

42 Exploring the Treatment Gap in High-Risk HR+, HER2– Early Breast Cancer: Eligible Patients Not Receiving Abemaciclib in the US

Ana Sandoval;Joyce A. O’Shaughnessy;Astra M. Liepa;Brenda Grimes;Katheryn Moreira;James Roose;Catherine Keane;Sara M. Tolaney, MD, MPH
May 29th 2025
Article

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

Heather McArthur, MD, MPH;Rebecca Dent, MD;Rina Hui;Yeon Hee Park;Peter Schmid, MD;Jing Wei;Jaime Mejia;Wilbur Pan;Javier Cortés, MD
May 27th 2025
Article

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.


48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status

Anushree Iyengar;Sandhya Mehta;Hannah Barman;Nivedita Rangarajan;Sue-Ann Woo;Simone T. Sredni;Rosemarie Di Donato;Safak Simsek;Erinn P. Downs;Aziza Nassar;Darren M. Wilson;Katherine Krieser;Elise Bieri Patzke;Natalie Kyek;Jason Hipp;Tyler Wagner, PhD
May 25th 2025
Article

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval

Katheryn Moreira;Kathryn Hudson;Wambui Gathirua-Mwangi;Zhanglin Lin Cui;Madeline Richey;Brenda Grimes;Jingru Wang;Astra Liepa;Erich Brechtelsbauer;Raisa Volodarsky;Hatem Soliman, MD
May 24th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.